

09-J0000-29

Original Effective Date: 10/15/99

Reviewed: 12/13/23

Revised: 09/15/24

Subject: Botulinum Toxins

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Dosage/ Administration	Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions
Related Guidelines	Other	References	Updates		

DESCRIPTION:

Botulinum toxin has been used for a wide variety of conditions in which the principal therapeutic aim is to reduce undesired or excessive contraction of striated or smooth (involuntary) muscle. There are six commercially available botulinum toxin type A preparations, onabotulinumtoxinA (Botox), incobotulinumtoxinA (Xeomin), abobotulinumtoxinA (Dysport), prabotulinumtoxinA (Jeuveau), daxibotulinumtoxinA-lanm (Daxxify), and letibotulinumtoxinA-wlbg (Letybo); and one botulinum toxin type B preparation, rimabotulinumtoxinB (Myobloc) available in the US. Jeuveau and Letybo are indicated for cosmetic use only. Because the potency of each botulinum toxin preparation is specific to the preparation and assay method, units of biologic activity for different preparations of botulinum toxin cannot be compared with or converted to units of other botulinum toxins. While therapy with botulinum toxin is relatively expensive considering the drug and administration costs and its effects are temporary and palliative (i.e., not curative) because of regeneration of nerve terminals in the affected muscle(s), treatment with botulinum toxin may provide an alternative to, or delay, more invasive and more costly interventions (e.g., surgery) and/or provide treatment for conditions for which few, if any, other effective therapies exist. Botulinum toxin also may be used in combination with other treatments to enhance efficacy. Because botulinum toxin prevents release of acetylcholine through denervation of cholinergic nerve terminals, the toxin also is used for autonomic disorders involving excessive glandular secretion (e.g., primary [axillary hyperhidrosis](#)) that is controlled by cholinergic transmission.

OnabotulinumtoxinA (Botox) is FDA-approved for the prophylaxis of headaches in adult patients with chronic migraine. The manufacturer conducted a double-blind, placebo-controlled study (NCT01662492) in adolescents aged 12 to 18 years with chronic migraine (migraines for longer than 6 months, with more than 15 headache days in a 4-week period) to assess efficacy in non-adult patients. Subjects were randomized to receive 155 units of Botox (n=45), 74 units of Botox (n=43), or placebo (normal saline) (n=37) over a 12-week trial. The mean change in frequency of headache days per 28-day period from

baseline was similar across all groups (placebo -6.8; 74 units of Botox -6.4; 155 units of Botox -6.3). There was no significant difference in percentage of patients with a 50% reduction or greater in frequency of headache days across groups (placebo 30%; 74 units of Botox 33%, 155 units of Botox 29%). No serious adverse events were seen in the placebo group. Serious adverse events were seen in 5% of those treated with 74 units of Botox (1 appendicitis, 1 migraine) and in 2% of those treated with 155 units of Botox (1 cellulitis). Other adverse events were reported in 22% of those treated with placebo, 32% of those treated with 74 units of Botox, and 19% of those treated with 155 units of Botox. The most common side effects seen more in treated groups were neck pain (9% of those receiving Botox vs. 0% of those receiving placebo) and musculoskeletal pain (5% of those receiving Botox vs 0% of those receiving placebo).

POSITION STATEMENT:

Initiation of botulinum toxin [excluding letibotulinumtoxinA (Letybo) and prabotulinumtoxinA (Jeveau)] **meets the definition of medical necessity** when **ALL** of the following criteria are met (“1”, “2”, and “3”):

1. The drug is being administered for the treatment of an indication listed in Table 1, and **ALL** of the indication specific and maximum dose criteria are met
2. The botulinum toxin requested is **NOT** to be used concurrently with a different botulin toxin (even if they are to be used for different indications)
3. If a member is being treated for multiple indications, the total cumulative dosage across all indications must not exceed the following:
 - a. Botox - 400 units every 12 weeks
 - b. Daxxify – 300 units every 12 weeks
 - c. Dysport - 1,500 units every 12 weeks
 - d. Myobloc - 15,000 units every 12 weeks
 - e. Xeomin - 400 units every 12 weeks

TABLE 1:

Indications and Specific Criteria		
Neurologic		
Indication	Criteria	Maximum Allowable Dose (per 12 weeks)
Blepharospasm	When blepharospasm is characterized by intermittent or sustained closure of the eyelids caused by involuntary contractions of the orbicularis oculi muscle	Botox: 100 units (50 units per eye) [billing max of 100 units]

		<p>Xeomin: 100 units (50 units per eye)</p> <p>[billing max of 100 units]</p>
<p>Cervical dystonia (including spasmodic torticollis)</p>	<p>When ALL of the following are met:</p> <ul style="list-style-type: none"> • Cervical dystonia is associated with sustained head tilt OR abnormal posturing with limited range of motion in the neck • Member has a history of recurrent, involuntary contraction of one or more of the muscles of the neck (e.g., sternocleidomastoid, splenius, trapezius, or posterior cervical muscles) • Alternative causes of the member's symptoms have been ruled out (e.g., chronic neuroleptic treatment, contractures, or other neuromuscular disorders) 	<p>Botox: 300 units</p> <p>[billing max of 300 units]</p> <p>Daxxify: 300 units</p> <p>[billing max of 300 units]</p> <p>Dysport:</p> <ul style="list-style-type: none"> • Initial: 500 units • Maintenance: 1,000 units <p>[billing max of 500 units]</p> <p>[billing max of 1,000 units]</p> <p>Myobloc: 10,000 units</p> <p>[billing max of 10,000 units]</p> <p>Xeomin: 300 units</p> <p>[billing max of 300 units]</p>
<p>Essential tremor affecting the arms and/or hands</p>	<p>When BOTH of the following are met:</p> <ul style="list-style-type: none"> • Member has had an inadequate response to at least 2 months of continuous treatment with or had an intolerance to at least TWO of the following, OR has contraindications to ALL of the following - if applicable, the specific intolerance(s) and/or contraindication(s) must be provided: <ul style="list-style-type: none"> ○ Propranolol (Inderal) 	<p>Botox: 200 units (100 each side)</p> <p>[billing max of 200 units]</p> <p>Xeomin: 200 units (100 each side)</p> <p>[billing max of 200 units]</p>

	<ul style="list-style-type: none"> ○ Primidone (Mysoline) ○ Alprazolam (Xanax) ○ Atenolol (Tenormin) ○ Clonazepam (Klonopin) ○ Gabapentin (Neurontin) ○ Topiramate (Topamax) ○ Sotalol (Betapace) ● Condition results in significant functional impairment (e.g., affects activities of daily living, including writing and eating) 	
<p>Focal dystonias</p> <ul style="list-style-type: none"> ● Focal upper limb dystonia (e.g., organic writer’s cramp) ● Laryngeal dystonia (adductor/abductor spasmodic dysphonia) ● Oromandibular dystonia ● Orofacial dyskinesia ● Cranial dystonia (Meige syndrome) 	<p>When EITHER of the following is met:</p> <ul style="list-style-type: none"> ● Condition results in significant functional impairment (e.g., interference with joint function, mobility, communication, nutritional intake) ● Member experiences pain as a result of the condition 	<p>Botox: 360 units [billing max of 400 units]</p> <p>Xeomin: 400 units [billing max of 400 units]</p>
<p>Hemifacial spasm (seventh cranial nerve disorders)</p>	<p>Condition is characterized by sudden, unilateral, synchronous contractions of muscles innervated by the facial nerve</p>	<p>Botox: 25 units [billing max of 100 units]</p> <p>Xeomin: 25 units [billing max of 50 units]</p>
<p>Chronic migraine prophylaxis[†] in adults</p>	<p>When ALL of the following criteria are met:</p> <ul style="list-style-type: none"> ● Member is 18 years of age or older ● Member meets BOTH of the following diagnostic criteria for chronic migraine – supportive medical record documentation 	<p>Botox: 155 units [billing max of 200 units]</p> <p>Xeomin: 155 units [billing max of 200 units]</p>

	<p>must be submitted, and must also include the specific number or an approximate range of patient-reported headache and migraine days in the prior month:</p> <ul style="list-style-type: none">○ Member has headaches for 15 or more days per month, each headache lasts for 4 hours or more, and duration is greater than 3 months○ On at least 8 days (of the 15 days per month) per month for greater than 3 months, the headache is classified as migraine[†] with aura or without aura● The prescriber is a headache specialist (e.g. neurologist; pain management specialist; or specialist with United Council for Neurologic Subspecialties [UCNS] certification) or the prescriber has consulted with a headache specialist● EITHER of the following:<ul style="list-style-type: none">○ Member has had an inadequate response to at least 6 weeks of continuous treatment, at a generally accepted dose, with at least ONE medication selected from any of the following classes of migraine prophylaxis medications:<ul style="list-style-type: none">- CGRP receptor antagonists FDA-approved for migraine prophylaxis [e.g., atogepant (Qulipta), eptinezumab (Vyapti), erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), rimegepant (Nurtec)]- Non-SSRI antidepressants (e.g., amitriptyline,	
--	--	--

	<p>clomipramine, doxepin, mirtazapine, nortriptyline, venlafaxine)</p> <ul style="list-style-type: none"> - Antiepileptics (e.g., divalproex, gabapentin, topiramate) - Beta-blockers (e.g., atenolol, metoprolol, nadolol, propranolol, timolol); - Calcium channel blockers (e.g., diltiazem, nifedipine, nimodipine, verapamil) <ul style="list-style-type: none"> o Member has contraindications to ALL five classes of medications – the specific contraindications must be provided 	
<p>Spastic conditions affecting the upper and/or lower limbs</p> <ul style="list-style-type: none"> • Cerebral palsy • Cerebrovascular accident (stroke) • Spinal cord injury • Traumatic brain injury • Hereditary spastic paraplegia • Multiple Sclerosis • Neuromyelitis optica • Schilder’s disease • Spastic hemiplegia • Transverse myelitis • Demyelinating diseases of CNS 	<p>When BOTH of the following are met:</p> <ul style="list-style-type: none"> • EITHER of the following: <ul style="list-style-type: none"> o Condition results in functional impairment (e.g., interference with joint function, mobility, communication, nutritional intake) o Member experiences pain as a result of the condition • Surgical intervention is considered to be the last option 	<p>Dysport: 1,500 units [billing max of 1,500 units]</p> <p>Botox: 400 units [billing max of 400 units]</p> <p>Xeomin: 400 units [billing max of 400 units]</p>
<p>Torsion dystonia</p>	<p>When EITHER of the following is met:</p> <ul style="list-style-type: none"> • Condition results in functional impairment (e.g., interference with 	<p>Botox: 360 units [billing max of 400 units]</p>

(including primary/genetic (idiopathic) and acquired (symptomatic))	joint function, mobility, communication, nutritional intake) <ul style="list-style-type: none"> Member experiences pain as a result of the condition 	Xeomin: 360 units [billing max of 400 units]
Exocrine		
Indication	Criteria	Maximum Allowable Dose (per 12 weeks)
Primary hyperhidrosis affecting the palms of hands, soles of feet, and/or axilla	When ALL of the following are met: <ul style="list-style-type: none"> Potential causes of secondary hyperhidrosis have been ruled out (e.g., hyperthyroidism) Condition is refractory to at least 2 months of continuous treatment with a topical agent (e.g., ≥10% aluminum chloride) unless use results in severe dermatitis EITHER of the following: <ul style="list-style-type: none"> The condition is associated with significant functional impairment (e.g., member is unable to perform age-appropriate activities of daily living) The condition is causing persistent or chronic cutaneous conditions (e.g., skin maceration, dermatitis, fungal infections, secondary microbial infections) 	Botox: 50 units per site, not to exceed 300 units if all six sites are affected <ul style="list-style-type: none"> Palms of hands: two sites, 100 units total Soles of feet: two sites, 100 units total Axilla: two sites, 100 units total [billing max of 300 units] Xeomin: 50 units per site, not to exceed 300 units if all six sites are affected <ul style="list-style-type: none"> Palms of hands: two sites, 100 units total Soles of feet: two sites, 100 units total Axilla: two sites, 100 units total [billing max of 300 units]
Chronic sialorrhea (excessive salivation)	When ALL of the following are met: <ul style="list-style-type: none"> Member has ANY of the following conditions: 	Botox: <ul style="list-style-type: none"> 100 units (e.g., 30 units to each parotid gland)

	<ul style="list-style-type: none"> ○ Amyotrophic lateral sclerosis (ALS) ○ Atypical parkinsonian disorders ○ Cerebral palsy ○ Parkinson disease (PD) ○ Stroke ○ Traumatic brain injury ● Member has experienced excessive salivation for 3 or more months ● Member is refractory to at least 2 months of continuous treatment with, had intolerable adverse effects with, or has a contraindication to at least one oral pharmacotherapy (e.g., anticholinergics) – if applicable, the specific intolerance or contraindication must be provided 	<p>and 20 units to each submandibular gland) [billing max of 100 units]</p> <p>Myobloc:</p> <ul style="list-style-type: none"> ● 3,500 units (e.g., 1,500 units to each parotid gland and 250 units to each submandibular gland) [billing max of 5,000units] <p>Xeomin:</p> <ul style="list-style-type: none"> ● <27 kg (60 lbs.): 50 units [billing max of 50 units] ● ≥27 kg (60 lbs.): 100 units (e.g., 30 units to each parotid gland and 20 units to each submandibular gland) [billing max of 100 units]
<p>Gustatory sweating (e.g., Frey’s Syndrome, diabetic gustatory sweating)</p>	<p>When ALL of the following are met:</p> <ul style="list-style-type: none"> ● Other potential causes of hyperhidrosis (e.g., hyperthyroidism) have been ruled out, or have been adequately treated ● EITHER of the following: <ul style="list-style-type: none"> ○ The condition is associated with significant functional impairment (e.g., member is unable to perform age-appropriate activities of daily living) ○ The condition is causing persistent or chronic cutaneous conditions (e.g., skin 	<p>Botox: 65 units [billing max of 100 units]</p> <p>Xeomin: 65 units [billing max of 100 units]</p>

	<p>maceration, dermatitis, fungal infections, secondary microbial infections)</p> <ul style="list-style-type: none"> For gustatory sweating that is NOT Frey’s syndrome – member has had an inadequate response to treatment with at least 2 months of continuous treatment with a topical medication (e.g., ≥10% aluminum chloride or anticholinergic) unless use results in severe dermatitis 	
--	---	--

Gastrointestinal

Indication	Criteria	Maximum Allowable Dose (per 12 weeks)
Chronic anal fissure	<p>Member has had an inadequate response to at least ONE of the following topical treatments:</p> <ul style="list-style-type: none"> Topical nitroglycerin Topical calcium channel blocker (e.g., diltiazem, nifedipine) 	<p>Botox: 25 units [billing max of 100 units]</p> <p>Xeomin: 25 units [billing max of 50 units]</p>
Esophageal achalasia	<p>When ALL of the following are met:</p> <ul style="list-style-type: none"> The member’s diagnosis has been confirmed by esophageal manometry EITHER of the following is met: <ul style="list-style-type: none"> Member has had an inadequate response to previous pneumatic dilation therapy or myotomy Member is considered a poor candidate for dilation/myotomy as evidenced by ONE or more of the following <ul style="list-style-type: none"> Sigmoid-shaped esophagus 	<p>Botox: 100 units [billing max of 100 units]</p> <p>Xeomin: 100 units [billing max of 100 units]</p>

	<ul style="list-style-type: none"> - Previous dilation-induced perforation - Epiphrenic diverticulum or hiatal hernia - High risk for complications of myotomy or pneumatic dilation (e.g., member has esophageal reflux or perforation) - Member has a limited life expectancy 	
Hirschsprung disease	<p>When ALL of the following are met:</p> <ul style="list-style-type: none"> • Member has obstructive symptoms caused by a non-relaxing internal anal sphincter • Member experienced symptoms following surgery for their disease 	<p>Botox: 100 units [billing max of 100 units]</p> <p>Xeomin: 100 units [billing max of 100 units]</p>
Ophthalmologic		
Indication	Criteria	Maximum Allowable Dose (per 12 weeks)
Strabismus disorders in adults	<p>When BOTH of the following are met:</p> <ul style="list-style-type: none"> • ONE or more of the following characteristics are present: <ul style="list-style-type: none"> ○ Horizontal strabismus up to 50 prism diopters ○ Vertical strabismus ○ Persistent sixth nerve palsy of one month or longer • Member has one or more of the following symptoms: <ul style="list-style-type: none"> ○ Diplopia ○ Impaired depth perception ○ Impaired peripheral vision 	<p>Botox: 25 units [billing max of 100 units]</p> <p>Xeomin: 25 units [billing max of 50 units]</p>

	<ul style="list-style-type: none"> ○ Impaired ability to maintain fusion 	
Strabismus disorders in children (including infantile esotropia)	Diagnosis only	<p>Botox: 25 units [billing max of 100 units]</p> <p>Xeomin: 25 units [billing max of 50 units]</p>
Urologic		
Indication	Criteria	Maximum Allowable Dose (per 12 weeks)
Urinary incontinence	<p>When ALL of the following are met:</p> <ul style="list-style-type: none"> • Condition is due to detrusor overactivity associated with a neurologic condition (e.g., spinal cord injury or multiple sclerosis) that has been confirmed by urodynamic testing • Member has failure of behavioral therapy (e.g., bladder training, habit training, biofeedback, and pelvic muscle exercises) • EITHER of the following: <ul style="list-style-type: none"> ○ Member has had an inadequate response to at least 2 months of continuous treatment with or intolerance to at least ONE prescription antimuscarinic (e.g., oxybutynin [Ditropan, Ditropan XL], tolterodine [Detrol, Detrol LA] solifenacin [Vesicare], trospium [Sanctura, Sanctura XR], darifenacin [Enablex], fesoterodine [Toviaz]) – if applicable, the specific intolerance must be provided 	<p>Botox: 200 units [billing max of 200 units]</p> <p>Xeomin: 200 units [billing max of 200 units]</p>

	<ul style="list-style-type: none"> ○ Member has a documented contraindication to ALL oral antimuscarinics - the specific contraindication(s) must be provided 	
<p>Neurogenic detrusor overactivity</p> <p>[pediatric patients ONLY]</p>	<p>When ALL of the following are met:</p> <ul style="list-style-type: none"> ● Member is at least 5 years of age but less than 18 years of age [refer to the urinary incontinence criteria above for adult members] ● Condition is due to detrusor overactivity associated with a neurologic condition (e.g., spinal cord injury, spinal dysraphism such as spinal bifida) that has been confirmed by urodynamic testing ● EITHER of the following: <ul style="list-style-type: none"> ○ Member has had an inadequate response to at least 2 months of continuous treatment with or intolerance to at least ONE prescription antimuscarinic appropriate for pediatric use (e.g., oxybutynin [Ditropan, Ditropan XL], solifenacin [Vesicare], trospium [Sanctura, Sanctura XR]) – if applicable, the specific intolerance must be provided ○ Member has documented contraindications to BOTH oxybutynin AND solifenacin - the specific contraindication(s) must be provided 	<p>Botox:</p> <ul style="list-style-type: none"> ● <34 kg (75 lbs.): 6 units/kg [billing max of 100 units if 17 kg (37 lbs.) or less] ● ≥34 kg (75 lbs.): 200 units [billing max of 200 units greater than 17 kg (37 lbs.)]
<p>Overactive bladder (OAB)</p>	<p>When ALL of the following are met:</p> <ul style="list-style-type: none"> ● Member has symptoms of urge urinary incontinence, urgency, or frequency ● Member has failure of behavioral therapy (e.g., bladder training, habit training, biofeedback, and pelvic muscle exercises) 	<p>Botox: 100 units [billing max of 100 units]</p> <p>Xeomin: 100 units [billing max of 100 units]</p>

	<ul style="list-style-type: none"> • EITHER of the following: <ul style="list-style-type: none"> ○ Member has had an inadequate response to at least 2 months of continuous treatment with or intolerance(s) to at least TWO prescription antimuscarinics (e.g., oxybutynin [Ditropan, Ditropan XL], tolterodine [Detrol, Detrol LA] solifenacin [Vesicare], trospium [Sanctura, Sanctura XR], darifenacin [Enablex], fesoterodine [Toviaz]) – if applicable, the specific intolerance(s) must be provided ○ Member has documented contraindications to ALL oral antimuscarinics - the specific contraindication(s) must be provided 	
<p>Approval duration: 6 months</p> <p>†Diagnostic criteria for migraine with aura and without aura are located in the section entitled “OTHER.”</p>		

Continuation of botulinum toxin [excluding letibotulinumtoxinA (Letybo) and prabotulinumtoxinA (Jeuveau)] treatment **meets the definition of medical necessity** when **ALL** of the following criteria are met (“1” to “6”):

1. Authorization or reauthorization has been previously approved by Florida Blue or another health plan in the past 2 years for the treatment of an indication listed in Table 1, **OR** the member previously met **ALL** indication-specific initiation criteria.
2. Member has demonstrated a beneficial response to therapy.
3. For chronic migraine prophylaxis **ONLY** – Member has had a beneficial response to therapy as evidenced by following:
 - Less than 12 months of treatment – **EITHER** of the following (“i” or “ii”):
 - i. Headache frequency was reduced by 7 days per month or more (when compared to pre-treatment average) by the end of the initial trial
 - ii. Headache duration was reduced by 100 total hours per month or more (when compared to pre-treatment average) by the end of the month

- 12 or more months of treatment – the member continues to maintain a clinically meaningful reduction in headache frequency and/or headache duration
4. The botulinum toxin requested is **NOT** to be used concurrently with a different botulin toxin (even if they are to be used for different indications)
 5. If a member is being treated for multiple indications, the total cumulative dosage across all indications must not exceed the following, **unless** previously approved by Florida Blue:
 - a. Botox - 400 units every 12 weeks
 - b. Daxxify: 300 units every 12 weeks
 - c. Dysport - 1,500 units every 12 weeks
 - d. Myobloc - 15,000 units every 12 weeks
 - e. Xeomin - 400 units every 12 weeks
 6. The dosage does not exceed the following in Table 2 based on the specific product and indication for use.

TABLE 2:

Indication	Maximum Allowable Dose (per 12 weeks)
Blepharospasm	Botox: 100 units (50 units per eye) [billing max of 100 units] Xeomin: 100 units (50 units per eye) [billing max of 100 units]
Cervical dystonia (including spasmodic torticollis)	Botox: 300 units [billing max of 300 units] Daxxify: 300 units [billing max of 300 units] Dysport: Initial: 500 units [billing max of 500 units] Maintenance: 1,000 units Myobloc: 15,000 units [billing max of 15,000 units] Xeomin: 300 units [billing max of 300 units]

Essential tremor of arm and/or hands	<p>Botox: 200 units (100 each side) [billing max of 200 units]</p> <p>Xeomin: 200 units (100 each side) [billing max of 200 units]</p>
<p>Focal dystonias</p> <ul style="list-style-type: none"> • Focal upper limb dystonia (e.g., organic writer's cramp) • Laryngeal dystonia (adductor/abductor spasmodic dysphonia) • Oromandibular dystonia • Orofacial dyskinesia • Cranial dystonia (Meige syndrome) 	<p>Botox: 360 units [billing max of 400 units]</p> <p>Xeomin: 400 units [billing max of 400 units]</p>
Hemifacial spasm (seventh cranial nerve disorders)	<p>Botox: 25 units [billing max of 100 units]</p> <p>Xeomin: 25 units [billing max of 50 units]</p>
Chronic migraine prophylaxis	<p>Botox: 155 units [billing max of 200 units]</p> <p>Xeomin: 155 units [billing max of 200 units]</p>
<p>Spastic conditions affecting the upper or lower limbs</p> <ul style="list-style-type: none"> • Cerebral palsy • Cerebrovascular accident (stroke) • Spinal cord injury • Traumatic brain injury • Hereditary spastic paraplegia • Multiple Sclerosis • Neuromyelitis optica • Schilder's disease • Spastic hemiplegia • Transverse myelitis • Demyelinating diseases of CNS 	<p>Dysport: 1,500 units [billing max of 1,500 units]</p> <p>Botox: 400 units [billing max of 400 units]</p> <p>Xeomin: 400 units [billing max of 400 units]</p>
Torsion dystonia (including primary/genetic (idiopathic) and acquired (symptomatic))	<p>Botox: 360 units [billing max of 400 units]</p> <p>Xeomin: 360 units [billing max of 400 units]</p>

<p>Primary hyperhidrosis affecting the palms of hands, soles of feet, and/or axilla</p>	<p>Botox: 50 units per site, not to exceed 300 units if all six sites are affected</p> <ul style="list-style-type: none"> • Palms of hands: two sites, 100 units total • Soles of feet: two sites, 100 units total • Axilla: two sites, 100 units total <p>[billing max of 300 units]</p> <p>Xeomin: 50 units per site, not to exceed 300 units if all six sites are affected</p> <ul style="list-style-type: none"> • Palms of hands: two sites, 100 units total • Soles of feet: two sites, 100 units total • Axilla: two sites, 100 units total <p>[billing max of 300 units]</p>
<p>Chronic sialorrhea (excessive salivation) due to amyotrophic lateral sclerosis (ALS), atypical parkinsonian disorder, cerebral palsy, Parkinson disease (PD), stroke, or traumatic brain injury</p>	<p>Botox:</p> <ul style="list-style-type: none"> • 100 units* (e.g., 30 units to each parotid gland and 20 units to each submandibular gland) [billing max of 100 units] <p>Myobloc:</p> <ul style="list-style-type: none"> • 3,500 units* (e.g., 1,500 units to each parotid gland and 250 units to each submandibular gland) [billing max of 5,000 units] <p>Xeomin:</p> <ul style="list-style-type: none"> • <27 kg (60 lbs.): 50 units* [billing max of 50 units] • ≥27 kg (60 lbs.): 100 units* (e.g., 30 units to each parotid gland and 20 units to each submandibular gland) [billing max of 100 units] <p><i>*A higher dose may be approved if the dose was previously approved via clinical review and authorization by Florida Blue.</i></p>
<p>Gustatory sweating (e.g., Frey Syndrome, diabetic gustatory sweating)</p>	<p>Botox: 65 units [billing max of 100 units]</p> <p>Xeomin: 65 units [billing max of 100 units]</p>
<p>Chronic anal fissure</p>	<p>Botox: 25 units</p>

	<p>[billing max of 100 units]</p> <p>Xeomin: 25 units [billing max of 50 units]</p>
Esophageal achalasia	<p>Botox: 100 units [billing max of 100 units]</p> <p>Xeomin: 100 units [billing max of 100 units]</p>
Hirschsprung disease	<p>Botox: 100 units [billing max of 100 units]</p> <p>Xeomin: 100 units [billing max of 100 units]</p>
Strabismus disorders in adults	<p>Botox: 25 units [billing max of 100 units]</p> <p>Xeomin: 25 units [billing max of 50 units]</p>
Strabismus disorders in children (including infantile esotropia)	<p>Botox: 25 units [billing max of 100 units]</p> <p>Xeomin: 25 units [billing max of 50 units]</p>
Overactive bladder (OAB)	<p>Botox: 100 units [billing max of 100 units]</p> <p>Xeomin: 100 units [billing max of 100 units]</p>
Neurogenic detrusor overactivity [pediatric patients ONLY (<18 years of age)]	<p>Botox:</p> <ul style="list-style-type: none"> • <34 kg (75 lbs.): 6 units/kg [billing max of 100 units if 17 kg (37 lbs.) or less] [billing max of 200 units greater than 17 kg (37 lbs.)] • ≥34 kg (75 lbs.): 200 units [billing max of 200 units]
Urinary incontinence	<p>Botox: 200 units [billing max of 200 units]</p> <p>Xeomin: 200 units [billing max of 200 units]</p>

Approval duration: 1 year

Botulinum toxin for the treatment chronic migraines in non-adults (i.e., patients less than 18 years of age) **does NOT meet the definition of medical necessity** based on lack of efficacy including data from a 12-week, multicenter, double-blind, placebo-controlled clinical trial showing that onabotulinumtoxinA (Botox) was no more effective than placebo [see Section 8.4 in the Botox Prescribing Information].

Botulinum toxin is considered **experimental or investigational** when administered for all other indications as additional controlled clinical trials are needed to demonstrate the safety and efficacy and there is insufficient clinical evidence to support its use, and specifically for the following:

- Anal spasm
- Anal sphincter dysfunction
- Bell's Palsy
- Benign essential tremor
- Benign prostatic hyperplasia (BPH)
- Biliary [dyskinesia](#) (Sphincter of Oddi dysfunction)
- [Blepharoplasty](#)
- Carpal tunnel syndrome
- Chronic motor tic disorder
- Chronic pain, chronic low back pain, chronic neck pain
- Clubfoot
- Depression
- Drooling (except chronic sialorrhea associated with ALS, atypical parkinsonian disorders, cerebral palsy, Parkinson disease, stroke, or traumatic brain injury)
- Episodic migraines
- Facial wound healing
- Fibromyositis/fibromyalgia
- Gastroparesis
- Interstitial cystitis
- Irritable colon
- Joint pain
- Lateral epicondylitis (tennis elbow)
- Mechanical neck disorders
- Myasthenia gravis
- Myofascial pain syndrome
- Neuropathic pain after neck dissection

- Non-migraine headaches
- Nystagmus
- Pain after hemorrhoidectomy or lumpectomy
- Painful cramps
- Parkinson’s disease
- Prevention of pain associated with breast reconstruction after mastectomy
- Secondary hyperhidrosis
- Stuttering
- Temporomandibular joint (TMJ) disorders
- Tinnitus
- Vaginismus

The use of botulinum toxin [including letibotulinumtoxinA (Letybo) and prabotulinumtoxinA (Jeuveau)] administered for the treatment of skin wrinkles (e.g., glabellar creases, smoker’s lines, lipstick lines, crow’s feet, laugh lines, wrinkled neck, and aging neck) **does NOT meet the definition of medical necessity**, as they are considered cosmetic in nature and generally contract excluded.

DOSAGE/ADMINISTRATION:

THIS INFORMATION IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE USED AS A SOURCE FOR MAKING PRESCRIBING OR OTHER MEDICAL DETERMINATIONS. PROVIDERS SHOULD REFER TO THE MANUFACTURER’S FULL PRESCRIBING INFORMATION FOR DOSAGE GUIDELINES AND OTHER INFORMATION RELATED TO THIS MEDICATION BEFORE MAKING ANY CLINICAL DECISIONS REGARDING ITS USAGE.

TABLE 3:

FDA-approved indications [†] and Dosing		
Product	FDA-approved Indications	Dose
Botox	Urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication	200 Units, as separate 1 mL injections across 30 sites into detrusor
	Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are	100 Units, as separate 0.5 mL injections across 20 sites into detrusor

	intolerant of an anticholinergic medication	
	Neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication	<p>If 34 kg (75 lbs.) or greater, 200 Units as separate 0.5 mL injections across 20 sites into detrusor</p> <p>If less than 34 kg (75 lbs.), 6 Units/kg body weight given as injections across 20 sites into detrusor. Refer to product labeling for a table of dilution instructions and final dosing based on patient weight.</p>
	Prophylaxis of headaches in adult patients with chronic migraine (≥ 15 days per month with headache lasting 4 hours a day or longer)	155 Units, as 0.1 mL injections per each site divided across 7 head/neck muscles
	<p>Spasticity in patients 2 years of age and older (includes upper and lower limbs)</p> <p>Limitations of Use: Botox has not been shown to improve upper extremity functional abilities, or range of motion at a joint affected by a fixed contracture.</p>	<p>Adult: Dosing in initial and sequential treatment sessions should be tailored to the individual based on the size, number and location of muscles involved, severity of spasticity, the presence of local muscle weakness, the patient's response to previous treatment, or adverse event history. The lowest recommended starting dose should be used, and no more than 50 Units per site should generally be administered. For upper limb spasticity, in clinical trials, doses ranging from 75 Units to 400 Units were divided among selected muscles. The recommended dose for treating lower limb spasticity is 300 Units to 400 Units divided among 5 muscles (gastrocnemius, soleus, tibialis posterior, flexor hallucis longus and flexor digitorum longus. In treating adult patients for one or more indications, the maximum cumulative dose should not exceed 400 Units, in a 3-month interval.</p> <p>Pediatric: The recommended dose for the upper limbs is 3 to 6 Units/kg divided among the affected muscles. The total dose administered per treatment session in the</p>

		upper limb should not exceed 6 Units/kg or 200 Units, whichever is lower. The recommended dose for the lower limbs is 4 to 8 units/kg divided among the affected muscles. The total dose administered per treatment session in the lower limb should not exceed 8 Units/kg or 300 Units, whichever is lower. When treating both lower limbs or the upper and lower limbs in combination, the total dose should not exceed the lower of 10 Units/kg or 340 Units, in a 3-month interval.
	Cervical dystonia in adults	Base dosing on the member's head and neck position, localization of pain, muscle hypertrophy, patient response, and adverse event history
	Severe primary axillary hyperhidrosis in adults that is inadequately managed with topical agents	50 Units per axilla
	Blepharospasm associated with dystonia (12 years of age and older)	1.25 Units to 2.5 Units into each of 3 sites per affected eye
	Strabismus (12 years of age and older)	1.25 Units to 2.5 Units in any one muscle
Daxxify	Cervical dystonia in adults	The recommended dose ranges from 125 Units to 250 Units given intramuscularly as a divided dose among affected muscles. In patients previously treated with another botulinum toxin, their past dose, response to treatment, duration of effect, and adverse event history should be taken into consideration when determining the initial dose. Limiting the dose injected into the sternocleidomastoid muscle may reduce the occurrence of dysphagia. When dose modification is necessary, dose adjustment can be made in 50 to 75 Unit increments according to the individual patient's response.

Dysport	Cervical dystonia in adults	500 Units as a divided dose among affected muscles. Doses above 1000 Units have not been systematically evaluated.
	Spasticity in patients 2 years of age and older (upper and lower limbs)	<p>Dosing should be tailored based on the size, number and location of muscles involved, severity of spasticity, the presence of local muscle weakness, the patient's response to previous treatment, and/or adverse reaction history with botulinum toxins.</p> <p>Dosing in clinical trials for upper limb spasticity in adults was between 500 Units and 1000 Units and for lower limb spasticity was between 1000 Units and 1500 Units. The maximum recommended total dose per treatment session (upper and lower limb combined) in adults is 1500 Units.</p> <p>Refer to the package labeling for dosing in pediatric patients.</p>
Myobloc	Cervical dystonia in adults	Recommended initial dosage is 2,500 to 5,000 Units divided among affected muscles in members with a history of tolerating botulinum toxin injections. Patients without a prior history of tolerating botulinum toxin injections should receive a lower initial dosage. Subsequent dosing should be determined by the patient's individual response.
	Chronic sialorrhea in adults	Recommended dosage is 1,500 Units to 3,500 Units divided among the parotid (500 to 1,500 Units per gland) and submandibular glands (250 Units per gland)
Xeomin	Cervical dystonia in adults	Recommended initial dosage is 120 Units per treatment session. In previously treated patients, their past dose, response to treatment, duration of effect, and adverse event history should be taken into consideration when determining the dose. The frequency of repeat treatments should

		be determined by clinical response but should generally be no more frequent than every 12 weeks.
	Blepharospasm in adults	In treatment-naïve patients, the recommended initial total dose is 50 Units (25 Units per eye). In patients previously treated with abotulinumtoxinA, their past dose, response to treatment, duration of effect, and adverse event history should be taken into consideration when determining the dose. The total dose should not exceed 100 Units per treatment session (50 Units per eye).
	Upper limb spasticity in adults	The dosage, frequency, and number of injection sites should be tailored to the individual patient based on the size, number, and location of muscles to be treated, severity of spasticity, presence of local muscle weakness, prior response to treatment, and adverse event history. In patients not previously treated with a botulinum toxin, initial dosing should begin at the low end of the recommended dosing range and titrated as clinically necessary. In clinical trials, doses up to 400 Units were divided among selected muscles and most patients were retreated between 12 and 14 weeks.
	Upper limb spasticity in pediatric patients (2 to 17 years of age), excluding spasticity caused by cerebral palsy	The exact dosage, frequency, and number of injection sites should be tailored to the individual patient based on size, number and localization of involved muscles; the severity of spasticity; and the presence of local muscle weakness. The maximum recommended dose is 8 Units/kg, divided among affected muscles, up to a maximum dose of 200 Units per single upper limb. If both upper limbs are treated, the total dosage should not exceed 16 Units/kg, up to a maximum of 400 Units. The timing for repeat treatment should be determined

		based on the clinical need of the patient; the frequency of repeat treatments should be no sooner than every 12 weeks. Most patients in clinical studies were retreated between 12 and 16 weeks.
	Chronic sialorrhea in patients 2 years of age and older	Recommended total dose per treatment session in adults (≥18 years of age) is 100 Units (i.e., 30 Units for each parotid gland and 20 Units for each submandibular gland). For pediatric patients (2 to 17 years of age), the dose is weight-based with total doses ranging from 20 to 75 Units per treatment session. Only children 27 kg (60 lbs.) or greater require a dose above 50 Units. Xeomin has not been studied in children weighing less than 12 kg. Refer to the package labeling for specific dosing recommendations. For both adults and children, repeat treatment should be determined based on the actual clinical need of the individual patient, and no sooner than every 16 weeks.
*Indications related to cosmetic procedures (e.g., reduction in appearance of glabellar lines) are not provided in this table.		

Drug Availability

- Botox: available as a single-use, sterile 100 Unit or 200 Unit vacuum-dried powder for reconstitution. Only Botox Cosmetic is available in a 50 Unit vial size.
- Daxxify: available as a single-use, sterile 50 Unit and 100 Unit vial for reconstitution
- Dysport: available as a single-use, sterile 300 Unit or 500 Unit vial for reconstitution
- Myobloc: available as a single-use in 2,500; 5,000; and 10,000 Unit sterile glass vials
- Xeomin: available as a single-use, sterile 50 Unit, 100 Unit, and 200 Unit vial for reconstitution

PRECAUTIONS:

Boxed Warning:

Postmarketing reports indicate that the effects of Botox and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks

after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

Contraindications

All products

- Hypersensitivity to any botulinum toxin preparation or to any of the components of the formulation
- Infection at the proposed injection site

Botox

- Intradetrusor Injections: acute urinary tract infection and/or acute urinary retention

Dysport

- Allergy to cow's milk protein

Warnings

- The potency units of botulinum toxin products are not interchangeable
- Care should be exercised when injecting in or near vulnerable anatomic structures
- Concomitant neuromuscular disorder may exacerbate clinical effects of treatment
- Use in caution in members with compromised respiratory function
- Corneal exposure and ulceration due to reduced blinking may occur when products are used for the treatment of blepharospasm
- Retrobulbar hemorrhages and compromised retinal circulation may occur when products are used for the treatment of strabismus
- Bronchitis and upper respiratory tract infections may occur when products are used for the treatment of limb spasticity
- Urinary retention: post-void residual urine volume should be monitored in members treated for detrusor overactivity associated with a neurologic condition who do not catheterize routinely, particularly in members with multiple sclerosis.
- Products contain human albumin; a theoretical risk for transmission of viral diseases and/or Creutzfeldt-Jakob disease (CJD) is possible but is considered extremely remote. No cases of transmission of either have ever been identified in association with licensed albumin or albumin contained in other licensed products.

BILLING/CODING INFORMATION:

The following codes may be used to describe:

HCPSC Coding:

J0585	Injection, onabotulinumtoxinA, 1 unit (Botox)
-------	---

J0586	Injection, abobotulinumtoxinA, 5 units (Dysport)
J0587	Injection, rimabotulinumtoxinB, 100 units (Myobloc)
J0588	Injection, incobotulinumtoxinA, 1 unit (Xeomin)
J0589	Injection, daxibotulinumtoxinA-lanm, 1 unit (Daxxify)
J3590	Unclassified biologics [for Jeuveau and Letybo only]

ICD-10 Diagnosis Codes That Support Medical Necessity of Botox (J0585) and Xeomin (J0588):

G11.4	Hereditary spastic paraplegia
G24.1	Genetic torsion dystonia
G24.3	Spasmodic torticollis
G24.4	Idiopathic orofacial dystonia
G24.5	Blepharospasm
G24.8	Other dystonia
G25.89	Other specified extrapyramidal and movement disorders
G35	Multiple sclerosis
G36.0	Neuromyelitis optica
G37.0	Diffuse sclerosis of central nervous system
G37.1	Central demyelination of corpus callosum
G37.2	Central pontine myelinolysis
G37.3	Acute transverse myelitis in demyelinating disease of central nervous system
G37.5	Concentric sclerosis [Balo] of central nervous system
G37.8	Other specified demyelinating diseases of central nervous system
G37.9	Demyelinating disease of central nervous system, unspecified
G43.001 – G43.009	Migraine without aura, not intractable
G43.011 – G43.019	Migraine without aura, intractable
G43.101 – G43.109	Migraine with aura, not intractable
G43.111 – G43.119	Migraine with aura, intractable
G43.401 – G43.409	Hemiplegic migraine, not intractable
G43.411 – G43.419	Hemiplegic migraine, intractable
G43.501 – G43.509	Persistent migraine aura without cerebral infarction, not intractable
G43.511 – G43.519	Persistent migraine aura without cerebral infarction, intractable
G43.601 – G43.609	Persistent migraine aura with cerebral infarction, not intractable
G43.611 – G43.619	Persistent migraine aura with cerebral infarction, intractable
G43.701 – G43.709	Chronic migraine without aura, not intractable
G43.711 – G43.719	Chronic migraine without aura, intractable
G43.801 – G43.809	Other migraine, not intractable
G43.811 – G43.819	Other migraine, intractable
G43.821 – G43.829	Menstrual migraine, not intractable
G43.831 – G43.839	Menstrual migraine, intractable
G43.901 – G43.909	Migraine, unspecified, not intractable
G43.911 – G43.919	Migraine, unspecified, intractable
G43.A0 – G43.A1	Cyclical vomiting

G43.B0 – G43.B1	Ophthalmoplegic migraine
G43.C0 – G43.C1	Periodic headache syndromes in child or adult
G43.D0 – G43.D1	Abdominal migraine
G43.E01 – G43.E09	Chronic migraine with aura, not intractable
G43.E11 – G43.E19	Chronic migraine with aura, intractable
G44.221	Chronic tension-type headache, intractable
G44.229	Chronic tension-type headache, not intractable
G51.2	Melkersson syndrome
G51.31 – G51.39	Clonic hemifacial spasm
G51.4	Facial myokymia
G51.8	Other disorders of facial nerve
G80.0 – G80.9	Cerebral palsy
G81.10 – G81.14	Spastic hemiplegia
G82.20 – G82.22	Paraplegia
G82.50 – G82.54	Quadriplegia
G83.0	Diplegia of upper limbs
G83.20 – G83.24	Monoplegia of upper limb
G83.4	Cauda equina syndrome
G83.81	Brown-Sequard syndrome
G83.82	Anterior cord syndrome
G83.89	Other specified paralytic syndromes
H02.049	Spastic entropion of unspecified eye, unspecified eyelid
H02.149	Spastic ectropion of unspecified eye, unspecified eyelid
H49.00 – H49.03	Third [oculomotor] nerve palsy
H49.10 – H49.13	Fourth [trochlear] nerve palsy
H49.20 – H49.23	Sixth [abducent] nerve palsy
H49.30 – H49.33	Total (external) ophthalmoplegia
H49.40 – H49.43	Total (external) ophthalmoplegia
H49.881 – H49.889	Other paralytic strabismus
H49.9	Unspecified paralytic strabismus
H50.00	Unspecified esotropia
H50.011 – H50.012	Monocular esotropia
H50.021 – H50.022	Monocular esotropia with A pattern
H50.031 – H50.032	Monocular esotropia with V pattern
H50.041 – H50.042	Monocular esotropia with other noncomitancies
H50.05	Alternating esotropia
H50.06	Alternating esotropia with A pattern
H50.07	Alternating esotropia with V pattern
H50.08	Alternating esotropia with other noncomitancies
H50.10	Unspecified exotropia
H50.111 – H50.112	Monocular exotropia
H50.121 – H50.122	Monocular exotropia with A pattern
H50.131 – H50.132	Monocular exotropia with V pattern

H50.141 – H50.142	Monocular exotropia with other noncomitancies
H50.15	Alternating exotropia
H50.16	Alternating exotropia with A pattern
H50.17	Alternating exotropia with V pattern
H50.18	Alternating exotropia with other noncomitancies
H50.21 – H50.22	Vertical strabismus
H50.30	Unspecified intermittent heterotropia
H50.311 – H50.312	Intermittent monocular esotropia
H50.32	Intermittent alternating esotropia
H50.331 – H50.332	Intermittent monocular exotropia
H50.34	Intermittent alternating exotropia
H50.40	Unspecified heterotropia
H50.411 – H50.412	Cyclotropia
H50.42	Monofixation syndrome
H50.43	Accommodative component in esotropia
H50.50	Unspecified heterophoria
H50.51	Esophoria
H50.52	Exophoria
H50.53	Vertical heterophoria
H50.54	Cyclophoria
H50.55	Alternating heterophoria
H50.60	Mechanical strabismus unspecified
H50.611 – H50.612	Brown's sheath syndrome
H50.69	Other mechanical strabismus
H50.811 – H50.812	Duane's syndrome
H50.89	Other specified strabismus
H50.9	Unspecified strabismus
H51.0	Palsy (spasm) of conjugate gaze
H51.11 – H51.12	Convergence insufficiency and excess
H51.20 – H51.23	Internuclear ophthalmoplegia
H51.8	Other specified disorders of binocular movement
I69.031 – I69.039	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage
I69.041 – I69.049	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage
I69.051 – I69.059	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage
I69.061 – I69.069	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage
I69.131 – I69.139	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage
I69.141 – I69.149	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage
I69.151 – I69.159	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage
I69.161 – I69.169	Other paralytic syndrome following nontraumatic intracerebral hemorrhage
I69.231 – I69.239	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage
I69.241 – I69.249	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage

I69.251 – I69.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage
I69.261 – I69.269	Other paralytic syndrome following other nontraumatic intracranial hemorrhage
I69.331 – I69.339	Monoplegia of upper limb following cerebral infarction
I69.341 – I69.349	Monoplegia of lower limb following cerebral infarction
I69.351 – I69.359	Hemiplegia and hemiparesis following cerebral infarction
I69.361 – I69.369	Other paralytic syndrome following cerebral infarction
I69.831 – I69.839	Monoplegia of upper limb following other cerebrovascular disease
I69.841 – I69.849	Monoplegia of lower limb following other cerebrovascular disease
I69.851 – I69.859	Hemiplegia and hemiparesis following other cerebrovascular disease
I69.861 – I69.869	Hemiplegia and hemiparesis following other cerebrovascular disease
I69.931 – I69.939	Monoplegia of upper limb following unspecified cerebrovascular disease
I69.941 – I69.949	Monoplegia of lower limb following unspecified cerebrovascular disease
I69.951 – I69.959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease
I69.961 – I69.969	Other paralytic syndrome following unspecified cerebrovascular disease
J38.5	Laryngeal spasm
K11.7	Disturbance of salivary secretion
K22.0	Achalasia of cardia
K22.5	Diverticulum of esophagus, acquired
K44.9	Diaphragmatic hernia without obstruction or gangrene
K60.2	Anal fissure, unspecified
L74.510	Primary focal hyperhidrosis, axilla
L74.511	Primary focal hyperhidrosis, face
L74.512	Primary focal hyperhidrosis, palms
L74.513	Primary focal hyperhidrosis, soles
L74.519	Primary focal hyperhidrosis, unspecified
L74.52	Secondary focal hyperhidrosis
M43.6	Torticollis
M62.40	Contracture of muscle, unspecified site
M62.838	Other muscle spasm
N31.8	Other neuromuscular dysfunction of bladder
N31.9	Neuromuscular dysfunction of bladder, unspecified
N32.81	Overactive bladder
N36.44	Muscular disorders of urethra
N39.41	Urge incontinence
N39.46	Mixed incontinence
N39.492	Postural (urinary) incontinence
Q43.1	Hirschsprung's disease
R35.0	Frequency of micturition
R49.0	Dysphonia
R49.8	Other voice and resonance disorders
R68.2	Dry mouth, unspecified

S04.9XXS	Injury of unspecified cranial nerve, sequel
S06.9X9S	Unspecified intracranial injury with loss of consciousness of unspecified duration, sequel
S14.109S	Unspecified injury at unspecified level of cervical spinal cord, sequel
S14.2XXS	Injury of nerve root of cervical spine, sequela
S14.9XXS	Injury of unspecified nerves of neck, sequel
S24.109S	Unspecified injury at unspecified level of thoracic spinal cord, sequela
S24.2XXS	Injury of nerve root of thoracic spine, sequel
S24.9XXS	Injury of unspecified nerve of thorax, sequel
S34.109S	Unspecified injury to unspecified level of lumbar spinal cord, sequela
S34.139S	Unspecified injury to sacral spinal cord, sequela
S34.21XS	Injury of nerve root of lumbar spine, sequel
S34.22XS	Injury of nerve root of sacral spine, sequel
S34.9XXS	Injury of unspecified nerves at abdomen, lower back and pelvis level, sequela

ICD-10 Diagnosis Codes That Support Medical Necessity of Daxxify (J0589):

G24.3	Spasmodic torticollis
M43.6	Torticollis

ICD-10 Diagnosis Codes That Support Medical Necessity of Dysport (J0586):

G11.4	Hereditary spastic paraplegia
G24.3	Spasmodic torticollis
G25.89	Other specified extrapyramidal and movement disorders
G35	Multiple sclerosis
G36.0	Neuromyelitis optica
G37.0	Diffuse sclerosis of central nervous system
G37.1	Central demyelination of corpus callosum
G37.2	Central pontine myelinolysis
G37.3	Acute transverse myelitis in demyelinating disease of central nervous system
G37.5	Concentric sclerosis [Balo] of central nervous system
G37.8	Other specified demyelinating diseases of central nervous system
G37.9	Demyelinating disease of central nervous system, unspecified
G80.0 – G80.9	Cerebral palsy
G81.10 – G81.14	Spastic hemiplegia
G82.20 – G82.22	Paraplegia
G82.50 – G82.54	Quadriplegia
G83.0	Diplegia of upper limbs
G83.20 – G83.24	Monoplegia of upper limb
G83.4	Cauda equina syndrome
G83.81	Brown-Sequard syndrome
G83.82	Anterior cord syndrome
G83.89	Other specified paralytic syndromes
I69.031 – I69.039	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage

I69.041 – I69.049	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage
I69.051 – I69.059	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage
I69.061 – I69.069	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage
I69.131 – I69.139	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage
I69.141 – I69.149	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage
I69.151 – I69.159	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage
I69.161 – I69.169	Other paralytic syndrome following nontraumatic intracerebral hemorrhage
I69.231 – I69.239	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage
I69.241 – I69.249	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage
I69.251 – I69.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage
I69.261 – I69.269	Other paralytic syndrome following other nontraumatic intracranial hemorrhage
I69.331 – I69.339	Monoplegia of upper limb following cerebral infarction
I69.341 – I69.349	Monoplegia of lower limb following cerebral infarction
I69.351 – I69.359	Hemiplegia and hemiparesis following cerebral infarction
I69.361 – I69.369	Other paralytic syndrome following cerebral infarction
I69.831 – I69.839	Monoplegia of upper limb following other cerebrovascular disease
I69.841 – I69.849	Monoplegia of lower limb following other cerebrovascular disease
I69.851 – I69.859	Hemiplegia and hemiparesis following other cerebrovascular disease
I69.861 – I69.869	Hemiplegia and hemiparesis following other cerebrovascular disease
I69.931 – I69.939	Monoplegia of upper limb following unspecified cerebrovascular disease
I69.941 – I69.949	Monoplegia of lower limb following unspecified cerebrovascular disease
I69.951 – I69.959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease
I69.961 – I69.969	Other paralytic syndrome following unspecified cerebrovascular disease
M43.6	Torticollis
S14.109S	Unspecified injury at unspecified level of cervical spinal cord, sequel
S14.2XXS	Injury of nerve root of cervical spine, sequela
S14.9XXS	Injury of unspecified nerves of neck, sequel
S24.109S	Unspecified injury at unspecified level of thoracic spinal cord, sequela
S24.2XXS	Injury of nerve root of thoracic spine, sequel
S24.9XXS	Injury of unspecified nerve of thorax, sequel
S34.109S	Unspecified injury to unspecified level of lumbar spinal cord, sequela
S34.139S	Unspecified injury to sacral spinal cord, sequela
S34.21XS	Injury of nerve root of lumbar spine, sequel
S34.22XS	Injury of nerve root of sacral spine, sequel
S34.9XXS	Injury of unspecified nerves at abdomen, lower back and pelvis level, sequela

ICD-10 Diagnosis Codes That Support Medical Necessity of Myobloc (J0587):

G24.3	Spasmodic torticollis
K11.7	Disturbance of salivary secretion

M43.6	Torticollis
R68.2	Dry mouth, unspecified

REIMBURSEMENT INFORMATION:

Injection of the vocal cords is done as an integral part of laryngoscopic guidance (31513, 31570, 31571), therefore does not warrant separate billing of the laryngoscope and injection.

Injection for treatment of achalasia requires a separate endoscopy procedure, which is billed and reimbursed separately.

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage Products:

No National Coverage Determination (NCD) was found at the time of the last guideline reviewed date.

The following Local Coverage Determination (LCD) located at www.fcso.com was reviewed on the last guideline reviewed date:

- Botulinum toxins, (L33274)

Medicare Part D: Florida Blue has delegated to Prime Therapeutics authority to make coverage determinations for the Medicare Part D services referenced in this guideline.

DEFINITIONS:

Abductor: any muscle that moves one part of the body away from another or away from the middle of the body.

Achalasia: idiopathic motility disorder of the esophagus characterized by a lack of peristalsis in the esophageal body and absent or incomplete relaxation of the lower esophageal sphincter (LES). There is no curative therapy for achalasia and both surgical (e.g., myotomy, pneumatic dilation) and nonsurgical palliative treatment modalities (e.g., botulinum toxin) have been developed with the aim of decreasing the LES pressure, thus facilitating esophageal emptying.

Anal fissure: tear in the anus

Axillary: armpit area

Blepharoplasty: any operation for the correction of a defect in the eyelids.

Blepharospasm: a twitching or spasmodic contraction of the orbicularis oculi muscle due to habit spasm, eyestrain, or nervous irritability.

Diverticulum: small pouch in the colon

Dyskinesia: involuntary movement

Dysphonia: any disorder with speech affecting voice quality or ability to produce voice.

Dystonia: a more general term describing a state of abnormal or disordered tonicity of muscle. Achalasia is an example of dystonia of the lower esophageal sphincter; cervical dystonia is also known as torticollis.

Esotropia: one or both eyes turning inward

Frey's Syndrome (gustatory sweating): redness and sweating on the cheek area adjacent to the ear.

Hiatal hernia: the protrusion of the upper part of the stomach into the thorax through a tear or weakness in the diaphragm.

Hyperhidrosis: excessive sweating.

Oromandibular dystonia: characterized by continuous, bilateral, asynchronous muscle spasms in the face, jaw, pharynx, and tongue causing difficulty in jaw closing or opening and interfering with fluid and food intake and speech; muscles of the neck, larynx, and respiratory system may be involved in severe cases.

Palmar: relating to the palm of the hand

Myotomy: surgical procedure in which muscle is cut. A common example of a myotomy is the Heller myotomy in which muscles of the cardia (lower esophageal sphincter or LES) are cut, allowing for food and liquids to pass to the stomach. It is used to treat achalasia.

Neuromyelitis optica: an inflammatory demyelinating disorder of the CNS in which the immune system attacks the optic nerves and spinal cord.

Pneumatic dilation: type of esophageal dilation in which a balloon is inserted in the deflated form into the area of narrowing. It is then inflated with air to a certain pressure that is pre-set for a given circumference.

Schilder's disease: a subacute or chronic form of leukoencephalopathy of children and adolescents.

Spasm: a sudden involuntary contraction of one or more muscle groups; includes cramps and contractures.

Spasticity: a disorder of muscle tone that occurs as the result of a variety of injuries to the central nervous system; characterized by a velocity-dependent increase in tonic-stretch reflexes with exaggerated tendon jerks.

Sternocleidomastoid: pertaining to the sternum, clavicle and mastoid process.

Strabismus: a visual disorder in which one eye cannot align with the other.

Torticollis: congenital or acquired stiff neck caused by spasmodic contraction of the neck muscles, drawing the head to one side with the chin pointing to the other side.

RELATED GUIDELINES:

[Treatment of Hyperhidrosis, 01-94010-08](#)

OTHER:

Migraine without aura diagnostic criteria

- A. At least five attacks fulfilling criteria B to D
- B. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)
- C. Headache has at least two of the following four characteristics:
 - 1. Unilateral location
 - 2. Pulsating quality
 - 3. Moderate or severe pain intensity
 - 4. Aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs)
- D. During headache at least one of the following:
 - 1. Nausea and/or vomiting
 - 2. Photophobia and phonophobia
- E. Not better accounted for by another ICHD-3 diagnosis.

Migraine with aura diagnostic criteria

- A. At least two attacks fulfilling criteria B and C
- B. One or more of the following fully reversible aura symptoms:
 - 1. Visual
 - 2. Sensory
 - 3. Speech and/or language
 - 4. Motor
 - 5. Brainstem
 - 6. Retinal
- C. At least three of the following six characteristics:
 - 1. At least one aura symptom spreads gradually over ≥ 5 minutes
 - 2. Two or more symptoms occur in succession
 - 3. Each individual aura symptom lasts 5 to 60 minutes
 - 4. At least one aura symptom is unilateral
 - 5. At least one aura symptom is positive
 - 6. The aura is accompanied, or followed within 60 minutes, by headache
- D. Not better accounted for by another ICHD-3 diagnosis

Chronic Migraine diagnostic criteria

- A. Headache (tension-type-like and/or migraine-like) on ≥ 15 days per month for > 3 months and fulfilling criteria B and C
- B. Occurring in a patient who has had at least five attacks fulfilling criteria B to D for Migraine without aura and/or criteria B and C for Migraine with aura
- C. On ≥ 8 days per month for > 3 months, fulfilling any of the following:
 - 1. Criteria C and D for Migraine without aura
 - 2. Criteria B and C for Migraine with aura
 - 3. Believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative
- D. Not better accounted for by another ICHD-3 diagnosis.

REFERENCES:

1. Albanese A, Abbruzzese G, Dressler D, et al. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. *J Neurol*. 2015; 262(10): 2201–2213.
2. Alrefai AH, Abjurahma SK, Khader YS. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo-controlled trial. *Clin Neurol Neurosurg*. 2009 Jan;111(1):79-82. Epub 2008 Nov 1.
3. Ambrogi V, Campione E., Mineo D, Paterno EJ, Pompeo E, Mineo TC. Bilateral thoracoscopic T2 to T3 sympathectomy versus botulinum injection in palmar hyperhidrosis. *Ann Thorac Surg*. 2009 Jul;88(1):238-45.
4. Baurtant E, Eggermont J, Faller E, et al. Use of botulinum toxin type A (XEOMIN) injections to the perineal muscles in case of perineal pain and dysfunction associated with pelvic floor muscle overcontraction and myalgia. *The Botulinum J*. 2013; 2, Nos. 3/4:215-216.
5. Benohanian A. What stands in the way of treating palmar hyperhidrosis as effectively as axillary hyperhidrosis with botulinum toxin type A. *Dermatol Online J*. 2009 Apr 15;15(4):12.
6. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2013 Jul 30;81(5):463-9.
7. Botox (onabotulinumtoxinA injection) [package insert]. Allergan, Inc.; Irvine, CA: November 2023.
8. Camilleri M, Kuo B, Nguyen L, et al. ACG Clinical Guideline: Gastroparesis. *Am J Gastroenterol*. 2022 Aug 1;117(8):1197-1220. Epub 2022 Jun 3.
9. Campanati A, Giuliadori K, Martina E, et al. Onabotulinumtoxin A (Botox) versus incobotulinum toxin A (Xeomin) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. *J Neural Transm* 2014; 121:21-6.
10. Castelnovo G, de Verdal M, Renard D, et al. Comparison of different sites of injections of incobotulinumtoxin (Xeomin) into the major salivary glands in drooling. *Movement Disorders*. 2013;28 (Suppl 1):S167.
11. Chinnapongse R, Pappert EJ, Evatt M, et al. An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinb in subjects with cervical dystonia. *Int J Neurosci*. 2010 Nov;120(11):703-10.
12. Church JT, Gadepalli SK, Talishinsky T, et al. Ultrasound-guided intrasphincteric botulinum toxin injection relieves obstructive defecation due to Hirschsprung's disease and internal anal sphincter achalasia. *J Pediatr Surg*. 2016 Oct 27.

13. Clinical Pharmacology powered by ClinicalKey [Internet]. Tampa, FL: Elsevier.; 2023. Available at: <https://www.clinicalkey.com/pharmacology/>. Accessed 11/22/23.
14. ClinicalTrials.gov. A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine. ClinicalTrials.gov Identifier: NCT01662492. Available at: <https://clinicaltrials.gov/ct2/show/NCT01662492>.
15. Comella CL, Jankovic J, Truon DD, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin, botulinum neurotoxin A, without accessory proteins) in patients with cervical dystonia. *J Neurol Sci* 2011; 308:103-9.
16. Coutinho dos Santos LH, Gomes AM, Giraldi S, Abagge KT, Marinoni LP. Palmar hyperhidrosis: long-term follow-up of nine children and adolescents treated with botulinum toxin type A. *Pediatr Dermatol*. 2009; 26(4):439-44.
17. Daxxify (botulinum toxin type A injection) [package insert]. Revance Therapeutics, Inc.; Newark, CA. November 2023.
18. Dressler D. Comparing Botox and Xeomin for axillar hyperhidrosis. *J Neural Transm* 2010; 117:317-19.
19. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. *Eur J Neurol*. 2009;16 (Suppl 2):2-5.
20. Dressler D, Pan L, and Bigalke H. Comparing incobotulinumtoxinA (Xeomin) and onabotulinumtoxinA (Botox): identical potency labelling in the hemidiaphragm assay. *J Neural Transm (Vienna)*. 2018 Jun 26. [Epub ahead of print].
21. Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. *Cochrane Database Syst Rev*. 2011 Dec 7;(12):CD005493.
22. Dysport (botulinum toxin type A injection) [package insert]. Ipsen Biopharmaceuticals, Inc.; Basking Ridge, NJ. September 2023.
23. Erasmus CE, van Hulst K, van den Hoogen FJ, van Limbeek J, Roeleveld N, Veerman EC, Rotteveel JJ, Jongerius PH. Thickened saliva after effective management of drooling with botulinum toxin A. *Dev Med Child Neurol*. 2010 Jun;52(6):e114-8. Epub 2010 Feb 12.
24. Gilio F, Iacovelli E, Frasca V, Gabriele M, Giacomelli E, Picchiori F, Soldo P, Cipriani AM, Ruoppolo G, Inghilleri M. Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: a clinical and neurophysiological study. *Amyotroph lateral Scler*. 2010 Aug;11(4):359-63.
25. Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis: a review. *Am J Clin Dermatol*. 2009; 10(2):87-102.
26. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018 Jan;38(1):1-211.
27. Incobotulinumtoxin A for the preventive treatment of chronic migraine headaches Poster presented at the 66th American Academy of Neurology Annual Meeting, April 26-May 3, 2014, Philadelphia, PA [2014 AAN Abstract].
28. Jankovic J, Comella C, Hanschmann A, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. *Mov Disord* 2011; 26(8):1521-1528.
29. Jeuveau (prabotulinumtoxinA-xvfx injection) [package insert]. Evolus Inc., Santa Barbara, CA: April 2023.
30. Kanovsky P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. *J Rehabil Med* 2011; 43:486-92.

31. Krel R, Mednick T, Spinner W. A Case Series: Use of IncobotulinumtoxinA (Xeomin) for Refractory Trigeminal Neuralgia. *Cephalalgia* 2013; 33(8): 152. [International headache congress 2013 Abstract].
32. Lacy BE, Tack J, Gyawali CP. AGA Clinical Practice Update on Management of Medically Refractory Gastroparesis: Expert Review. *Clin Gastroenterol Hepatol*. 2022 Mar;20(3):491-500.
33. Letybo (letibotulinumtoxinA-wlbg injection) [package insert]. Hugel, Inc.; Seoul South Korea: February 2024.
34. Li C, Wu F, Zhang Q, et al. Interventions for the treatment of Frey's syndrome. *Cochrane Database Syst Rev*. 2015 Mar 17;3: CD009959.
35. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. *J Urol*. 2019 Sep;202(3):558-563. Epub 2019 Aug 8.
36. Marques RE, Duarte GS, Rodrigues FB, et al. Botulinum toxin type B for cervical dystonia. *Cochrane Database Syst Rev*. 2016 May 13;(5):CD004315.
37. McConaghy JR, Fosselman D. Hyperhidrosis: Management Options. *Am Fam Physician*. 2018 Jun 1;97(11):729-734.
38. Messikh R, Atallah L, Aubin F, Humbert P. Botulinum toxin in disabling dermatological diseases. *Ann Dermatol Venereol*. 2009 May;136 Suppl 4: S129-36.
39. Micromedex Healthcare Series [Internet Database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed 11/22/23.
40. Miller RG, Jackson CE, Kasarskis EJ, et al., Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multi-disciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee [TRUNC]. *Neurology*. 2009 Oct 13;73(15):1227-33.
41. Myobloc (rimabotulinumtoxinB injection) [package insert]. Solstice Neurosciences, Inc., South San Francisco, CA: March 2021.
42. Nelson RL, Thomas K, Morgan J, et al. Non-surgical therapy for anal fissure. *Cochrane Database Syst Rev*. 2012 Feb 15;2:CD003431.
43. Oskoui M, Pringsheim T, Billingshurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2019 Sep 10;93(11):500-509. Epub 2019 Aug 14.
44. Pandey S, Srivanitchapoom P, Kirubakaran R, et al. Botulinum toxin for motor and phonic tics in Tourette's syndrome. *Cochrane Database Syst Rev*. 2018 Jan 5;1:CD012285.
45. Patel R, Halem M, Zaiac M. The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhidrosis with botulinum toxin injections. *J Drugs Dermatol*. 2009 Oct;8(10):948-51.
46. Peloso P, Gross A, Haines T, et al; Cervical Overview Group. Medicinal and injection therapies for mechanical neck disorders. *Cochrane Database Syst Rev*. 2007 Jul 18;(3):CD000319.
47. Pena AH, Cahill AM, Gonzalez L, Baskin KM, Kim H, Towbin RB. Botulinum toxin A injection of salivary glands in children with drooling and chronic aspiration. *J Vasc Interv Radiol*. 2009 Mar;20(3):368-73. Epub 2009 Jan 20.
48. Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. *Neurology*. 2019 May 7;92(19):896-906.

49. Proietti S, Giovannozzi S, Lepri E, et al. Clinical and urodynamic efficacy of Xeomin in the treatment of neurogenic detrusor overactivity: preliminary results. *Neurol Urol Urodyn*. 2011; 30 (suppl):45-46.
50. Quality Standards Subcommittee of the American Academy of Neurology, Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review). Report of the Quality Standards Subcommittee of the AAN and Practice Committee of the Child Neurology Society. *Neurology*. 2010 Jan 26;74(4):336-43.
51. Raval TH, Elliott CA. Botulinum toxin injection to the salivary glands for the treatment of sialorrhea with chronic aspiration. *Ann Otol Rhinol Laryngol*. 2008 Feb;117(2):118-22.
52. Rodrigues FB, Duarte GS, Marques RE, et al. Botulinum toxin type A therapy for cervical dystonia. *Cochrane Database Syst Rev*. 2020 Nov 12;11(11):CD003633.
53. Santamato A, Micello MF, Panza F, et al. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower-limb spasticity: a prospective open-label study. *Eur J Phys Rehabil Med* 2013; 49:483-9.
54. Scheffer AR, Erasmus C, van Hulst K, van Limbeek J, Jongerius PH, van den Hoogen FJ. Efficacy and duration of botulinum toxin treatment for drooling in 131 children. *Arch Otolaryngol Head Neck Surg*. 2010 Sep;136(9):873-7.
55. Silberstein SD, Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2000;55:754.
56. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016 May 10;86(19):1818-26.
57. Sriskandan N, Moody A, Howlett DC. Ultrasound-guided submandibular gland injection of botulinum toxin for hypersalivation in cerebral palsy. *Br J Oral Maxillofac Surg*. 2010 Jan;48(1):58-60. Epub 2009 Apr 15.
58. Subak LL, Quesenberry CP, Posner SF, et al. The effect of behavioral therapy on urinary incontinence: a randomized controlled trial. *Obstet Gynecol*. 2002 Jul;100(1):72-8.
59. Svetel M, Vasic M, Dragasevic N, Pekmezovic T, Petrovic I, Kostic V. Botulinum toxin in the treatment of sialorrhea. *Vojnosanit Pregl*. 2009 Jan;66(1):9-12.
60. Vaezi MF, Pandolfino JE, Yadlapati RH, et al. ACG clinical guideline: diagnosis and management of achalasia. *Am J Gastroenterol*. 2020 Sep;115(9):1393-1411.
61. Wald A, Bharucha AE, Limketkai B, et al. ACG Clinical Guidelines: Management of Benign Anorectal Disorders. *Am J Gastroenterol*. 2021 Oct 1;116(10):1987-2008.
62. Wester T, Granström AL. Botulinum toxin is efficient to treat obstructive symptoms in children with Hirschsprung disease. *Pediatr Surg Int*. 2015 Mar;31(3):255-9. doi: 10.1007/s00383-015-3665-4.
63. Wilken B, Aslami B, Backes H. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. *Neuropediatrics*. 2008 Aug;39(4):200-4. Epub 2009 Jan 22.
64. Xeomin (incobotulinumtoxinA injection) [package insert]. Merz North America, Inc.; Franksville, WI: September 2023.
65. Xie S, Wang K, Xu T, et al. Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles. *Cancer Med*. 2015 Nov;4(11):1639-50. Epub 2015 Aug 26.
66. Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the quality standards subcommittee of the American Academy of Neurology. *Neurology*. 2011;77(19):1752-55.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Pharmacy Policy Committee on 12/13/23.

GUIDELINE UPDATE INFORMATION:

10/15/99	Medical Coverage Guideline Reformatted.
01/01/01	Coding changes.
07/15/01	Revised.
01/01/02	Coding changes.
01/01/03	HCPCS coding update.
03/15/03	Moved Botox information from section entitled "Other" to "When Services are Covered".
12/15/03	Reviewed, revised to include criteria for covered indications; covered and non-covered indications expanded.
01/01/05	Added new primary axillary hyperhidrosis FDA indication, changed title, updated to new format.
08/15/05	Revised and Updated: added description, updated when services are covered, dosage/administration, precautions, CPT coding, ICD-9 diagnoses codes that support medical necessity, and references.
01/01/06	CPT code update. Revised codes: 31571, 64613, deleted expired code 90782.
02/15/06	Updated CPT coding: added 64614 chemo denervation of muscle(s), extremity (s), and/or trunk muscle (s) (e.g., for dystonia, cerebral palsy, multiple sclerosis).
05/15/06	Changed descriptor of CPT-4 code 92265 and added CPT-4 code 90772.
10/15/06	Revision consisting of adding CPT code 46505.
11/15/06	Removed ICD-9 codes until reviewed in January 2007.
01/01/07	MCG revised to include Medicare Part D as a program exception.
02/15/07	Annual Review; added indication for incontinence due to detrusor overactivity caused by spinal cord injury inadequately controlled by anticholinergic therapy. Reformatted and updated references.
04/15/07	Revision; consisting of adding CPT-4 codes 95872, 95873 & 95874 to range of codes.
06/15/07	Reformatted guideline.
11/15/07	Review and revision; consisting of rewriting the "Description" section, rewriting the "Dosage and Administration" section, removed Medicare Advantage from "Program Exceptions", and updated references.
01/01/09	Annual HCPCS coding update: deleted code 90772; added code 96372.
05/15/09	Review and revision; consisting of removing diagnosis of Equines foot, Infantile Cerebral Palsy, Neuromyelitis optica and spasticity with pain and adding drooling associated with Parkinson disease, reformatted guideline and updated references.
10/15/09	Revision; consisting of adding new drug, Dysport™, changing name of MCG, revising description, adding Precautions section and updating references.
01/01/10	Annual HCPCS coding update: added HCPCS code J0586 and revised descriptor for codes 95870, J0585, and J0587.

02/15/10	Review and revision; consisting of adding palmar hyperhidrosis as a covered indication and updating references.
11/15/10	Revision; consisting of adding description of new botulinum toxin and including in the position statement.
02/15/11	Review and revision; consisting of adding updating position statement coding and references.
04/01/11	Revision; consisting of updating codes.
08/05/11	Revision: changes to language around Certificate of Medical Necessity; grammatical changes.
01/01/12	Revision to guideline; consisting of updating codes.
02/15/11	Review and revision to guideline; consisting of updating position statement, precautions, coding and references.
11/15/12	Revision to guideline; consisting of clarifying blepharospasm and hyperhidrosis criteria.
02/15/13	Review and revision to guideline; consisting of reformatting and revising position statement to expand coverage to allow for treatment of essential tremor and gustatory sweating; revised description, dosage/administration, and precautions sections; updated references; added pertinent definitions.
03/15/13	Review and revision to guideline; consisting of revising position statement to include coverage of idiopathic overactive bladder and updating references.
05/15/13	Review and revision to guideline; consisting of adding quantity limit and approval duration.
01/15/14	Revision to guideline; consisting of adding continuation criteria.
02/15/14	Review and revision to guideline; consisting of updating the position statement and references.
09/15/14	Revision to guideline; consisting of revising position statement and updating references.
02/15/15	Review and revision to guideline, consisting of updating references
05/15/15	Revision; updated billing/coding
06/15/15	Revision to guideline, consisting of updating position statement and references.
11/01/15	Revision: ICD-9 Codes deleted.
11/15/15	Revision to guidelines, consisting of updating position statement based on a new FDA-approved indication for Dysport.
01/15/16	Revision to guidelines consisting of updating the position statement.
02/15/16	Revision to guidelines consisting of updating the position statement and references.
05/15/16	Revision to guidelines consisting of clarifying dosage limits in position statement, new FDA-approved indication for Botox, and revision of ICD-10 codes.
10/01/16	Revision: ICD-10 code updates and new FDA-approved indication for Dysport.
12/15/16	Revision: The re-dosing interval was modified from 90 days to 12 weeks with a corresponding authorization duration of 24 weeks
02/15/17	Review and revision to guideline consisting of updating the position statement and references.
07/15/17	Revision to guideline consisting of clarifying the position statement and updating the dosage/administration section.

11/15/17	Revision to guideline consisting of updating the position statement and dosage/administration section with a higher dosage limit for Dysport.
01/15/18	Review and revision to guideline consisting of updating the position statement, program exceptions, dosing/administration, precautions, and references.
07/15/18	Revision to guideline consisting of updating the position statement with an increased maximum dosage limit for Myobloc on continuation of therapy for cervical dystonia.
09/15/18	Revision to guideline consisting of updating the position statement, dosage/administration section, and references based on Xeomin's new FDA-approved indication of chronic sialorrhea in adults.
01/15/19	Review and revision to guideline consisting of updating the description section, position statement and references.
05/15/19	Revision to guideline consisting of updating the description, position statement, and references.
07/15/19	Revision to guideline consisting of updating the position statement, dosage/administration section, and references.
08/15/19	Revision to guideline consisting of updating the dosage/administration section and references.
01/15/20	Review and revision to guideline consisting of updating the position statement, dosage/administration, and references.
04/15/20	Revision to guideline consisting of updating the position statement and dosage/administration section.
09/01/20	Revision to guideline consisting of updating the position statement and dosage/administration section.
01/15/21	Review and revision to guideline consisting of updating the position statement, dosage/administration, and references.
02/15/21	Revision to guideline consisting of updating the position statement and dosage/administration section.
04/15/21	Revision to guideline consisting of updating the position statement, dosage/administration, and references.
05/15/21	Revision to guideline consisting of updating the position statement.
07/15/21	Revision to guideline consisting of updating the dosage/administration section and references.
01/15/22	Review and revision to guideline consisting of updating the position statement and references.
07/15/22	Revision to guideline consisting of updating the "Other" section.
01/15/23	Review and revision to guideline consisting of updating the description section, position statement, and references. Daxxify (daxibotulinumtoxinA-lanm) added as cosmetic use-only botulinum toxin. The separate CGRP receptor antagonists step requirement was moved into the single step requirement of at least one prophylactic migraine agent.
10/01/23	Revision: Added ICD-10 codes G43.E01 - G43.E09 and G43.E11 - G43.E19.
01/01/24	Revision: Added HCPCS codes C9160 and J3590.
01/15/24	Review and revision to guideline consisting of updating the description, position statement, dosage/administration, billing/coding, and references. Daxxify

	(daxibotulinumtoxinA-lanm) is now permitted for use in cervical dystonia with a maximum dosage of 300 units every 12 weeks, Initiation and continuation approval durations for all botulinum toxins updated to 6 months and 12 months, respectively.
04/01/24	Revision: Added HCPCS code J0589 and deleted codes C9160 and J3590. Letybo added as a cosmetic-use only botulinum toxin.
09/15/24	Revision: Added ICD-10 codes G51.31 – G51.39.